10/772,988 Examiner	THORGEIRSSON E	TAL.
		<u> </u>
	Artonit	
MINH-TAM DAVIS	1642	
ars on the cover sheet with this apport of the communication of the cover sheet s	correspondence addre oplication. If not include n will be mailed in due of to withdrawal from issue	od course. THIS e at the initiative
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF		
INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient. 5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted. (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) hereto or 2) to Paper No./Mail Date (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d). 6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
 Interview Summary Paper No./Mail Dat Examiner's Amenda 	(PTO-413), te <u>08/28/07</u> . ment/Comment	/ance
	(OR REMAINS) CLOSED in this appor other appropriate communication GHTS. This application is subject to and MPEP 1308. der 35 U.S.C. § 119(a)-(d) or (f). been received. been received in Application No cuments have been received in this communication to file a reply ENT of this application. tted. Note the attached EXAMINER is reason(s) why the oath or declarate to be submitted. on's Patent Drawing Review (PTO-Amendment / Comment or in the Comment or in the Comment or in the Comment or in the Communication of BIOLOGICAL MATERIAL in FOR THE DEPOSIT OF BIOLOGICAL MAT	ars on the cover sheet with the correspondence addres (OR REMAINS) CLOSED in this application. If not include or other appropriate communication will be mailed in due of GHTS. This application is subject to withdrawal from issue and MPEP 1308. der 35 U.S.C. § 119(a)-(d) or (f). been received. been received in Application No cuments have been received in this national stage application of this communication to file a reply complying with the requency of this application. tted. Note the attached EXAMINER'S AMENDMENT or NO is reason(s) why the oath or declaration is deficient. the submitted. on's Patent Drawing Review (PTO-948) attached Amendment / Comment or in the Office action of the length of the properties of the properties of the submitted. No is the submitted of the properties of the properti

Application/Control Number: 10/772,988

Art Unit: 1642

EXAMINER'S AMENDMENT

1) An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Brian Dorn on 08/29/07.

The application has been amended as follows:

In the claims:

Claims 2-3, 8-22, 24-32, 34, 36 were cancelled.

Claim 1 was amended as follows:

"a B5T Over-expressed Gene (BOG) polypeptide, said" on first and second lines was deleted.

"about" on third line was deleted.

--- the transcriptional factor --- was added before E2F-1 on sixth line.

Claim 23 was amended as follows:

"a BOG polypeptide" was deleted, and --- the BOG polypeptide --- was inserted.

Claim 33 was amended as follows:

"90%" on second line was deleted, and ---- 95% --- was inserted.

"SEQ ID NO:2," on second line was deleted.

"or SEQ ID NO:10" on second and third lines was deleted.

Application/Control Number: 10/772,988

Art Unit: 1642

--- the transcriptional factor --- was added before E2F-1 on sixth line.

Claim 45 was amended as follows:

The first "pRB" on the third line was deleted and --- the retinoblastoma gene product (pRB) --- was inserted.

--- the transcriptional factor --- was added before E2F-1 on third line.

2) The following is an examiner's statement of reasons for allowance:

The art does not teach or suggest the polypeptide SEQ ID NO:8, or a polypeptide having at least 90%, or 95% sequence identity with SEQ ID NO:8, wherein the polypeptide binds the tumor suppressor retinoblastoma gene product (pRB) and displaces the transcriptional factor E2F-1 bound to pRB. It is noted that: 1) E2F-1 when released from pRB mediates cell proliferation, and above a certain threshold, potentially apoptosis, and 2) deregulation of E2F-1 is found in the majority of human cancers (Seville et al, 2005, Current Cancer Drug Targets, 5: 159-170).

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MINH-TAM DAVIS whose telephone number is 571-272-0830. The examiner can normally be reached on 9:00 AM-5:30 PM.

Application/Control Number: 10/772,988

Art Unit: 1642

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

Page 4

supervisor, SHANON FOLEY can be reached on 571-272-0898. The fax phone number for the

organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published applications

may be obtained from either Private PAIR or Public PAIR. Status information for unpublished

applications is available through Private PAIR only. For more information about the PAIR

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR

system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would

like assistance from a USPTO Customer Service Representative or access to the automated

information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

MINH TAM DAVIS August 30, 2007

/Larry R. Helms/

Supervisory Patent Examiner